

Glycogen Storage Disease Type II

[View the current Glycogen Storage Disease Type II InDepth page on BioPortfolio.com \(PDF\)](#)

(http://www.bioportfolio.com/indepth/Glycogen_Storage_Disease_Type_II.html) - Regularly Updated.

Recent Publications on Glycogen Storage Disease Type II:



- [\[Pompe's disease. Part II. Treatment strategies and enzyme replacement\]](#)
Pompe's disease is an ultra-orphan disease caused by the deficiency of... 10th November, 2009
Pecs Tudományegyetem,- Ideggyógy Sz. 2009 Sep 30;62(9-10):299-307.
- [\[Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease.\]](#)
In a previous 52-wk trial, treatment with alglucosidase alpha markedly... 29th October, 2009
Department of Pediatrics, Duke University Medical Center, Durham, North- Pediatr Res. 2009 Sep;66(3):329-35. ([DOI Direct Link](#))
- [\[The Brazilian consensus on the management of Pompe disease.\]](#)
Pompe's disease is an ultra-orphan disease caused by the deficiency of... 23rd October, 2009
Departamento de Genética Médica, Instituto Fernandes Figueira/FIOCRUZ, Rio- J Pediatr. 2009 Oct;155(4 Suppl):S47-56. ([DOI Direct Link](#))
- [\[Treatment of gastroesophageal reflux with nissen fundoplication and gastrostomy tube insertion in infantile pompe's disease.\]](#)
In infantile Pompe's disease, enzyme replacement therapy (ERT) has been... 17th October, 2009
Department of General and Thoracic Surgery, University of Giessen,- Neuropediatrics. 2009 Feb;40(1):28-31. Epub 2009 Jul 28. ([DOI Direct Link](#))
- [\[Current enzyme replacement therapy for the treatment of lysosomal storage diseases.\]](#)
Glycogen storage disease type II (GSDII), also referred to as Pompe... 9th October, 2009
Regional Medical Genetics Center, N.Y. Medical College, Valhalla, NY- Pediatr Ann. 2009 Aug;38(8):448-55.
- [\[Adult onset glycogen storage disease type II \(adult onset Pompe disease\): report and magnetic resonance images of two cases.\]](#)
Glycogen storage disease type II (GSDII), also referred to as Pompe... 23rd September, 2009
Emory University School of Medicine, 1648 Pierce Drive, Atlanta, GA 30322,- Skeletal Radiol. 2009 Dec;38(12):1205-8. ([DOI Direct Link](#))
- [\[Immortalization of murine muscle cells from lysosomal alpha-glucosidase deficient mice: a new tool to study pathophysiology and assess therapeutic strategies for Pompe disease.\]](#)
Glycogen storage disease type II (GSDII) is an autosomal recessive... 22nd September, 2009
Institut Cochin, Université Paris Descartes. CNRS (UMR 8104), Paris,- Biochem Biophys Res Commun. 2009 Oct 16;388(2):333-8. Epub 2009 Aug 6. ([DOI Direct Link](#))
- [\[Pompe's disease. Part I: pathogenesis and clinical features\]](#)
Pompe's disease is an ultra-orphan disease caused by the deficiency of... 19th September, 2009
Pecs Tudományegyetem,- Ideggyógy Sz. 2009 Jul 30;62(7-8):231-43.

- [The values and limits of an in vitro model of Pompe disease: the best laid schemes o' mice an' men...](#)
In Pompe disease, a lysosomal glycogen storage disorder, cardiac and... 17th September, 2009
Arthritis and Rheumatism Branch, National Institute of Arthritis and- Autophagy. 2009 Jul;5(5):729-31.
- [Diagnostic criteria for late-onset \(childhood and adult\) Pompe disease.](#)
The diagnosis of late-onset (childhood and adult) Pompe disease can often... 26th August, 2009
- Muscle Nerve. 2009 Jul;40(1):149-60. ([DOI Direct Link](#))
- [Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory.](#)
Pompe disease (acid maltase deficiency; glycogen storage disease type II)... 26th August, 2009
Division of Medical Genetics, Department of Pediatrics, Biochemical- Muscle Nerve. 2009 Jul;40(1):32-6. ([DOI Direct Link](#))
- [Enzyme replacement therapy in adult-onset glycogenosis II: is quantitative muscle MRI helpful?](#)
Although it has been shown that muscle magnetic resonance imaging (MRI)... 26th August, 2009
Neuroradiology Department, IRCCS "C. Mondino Institute of Neurology"- Muscle Nerve. 2009 Jul;40(1):122-5. ([DOI Direct Link](#))
- [Impaired clearance of accumulated lysosomal glycogen in advanced Pompe disease despite high-level vector-mediated transgene expression.](#)
BACKGROUND: Infantile-onset glycogen storage disease type II (GSD-II)... 22nd July, 2009
Division of Medical Genetics, Department of Pediatrics, Duke University- J Gene Med. 2009 Oct;11(10):913-20. ([DOI Direct Link](#))
- [Silent exonic mutation in the acid-alpha-glycosidase gene that causes glycogen storage disease type II by affecting mRNA splicing.](#)
Glycogen-storage disease type II (GSDII) is an autosomal recessive... 18th July, 2009
Department of Pediatrics, Asahikawa Medical College, Asahikawa, Hokkaido,- J Hum Genet. 2009 Aug;54(8):493-6. Epub 2009 Jul 17. ([DOI Direct Link](#))
- [Pompe disease in a Brazilian series: clinical and molecular analyses with identification of nine new mutations.](#)
Pompe disease (glycogen storage disease type II or acid maltase... 10th July, 2009
Myopathies and Molecular Biology Group, Department of Neurology, School of- J Neurol. 2009 Nov;256(11):1881-90. Epub 2009 Jul 9. ([DOI Direct Link](#))

Glycogen Storage Disease Type II Patents:



- 7605249- [Treatment of neurodegenerative disease through intracranial delivery of siRNA](#)
- 6858425- [Human acid alpha glucosidase gene and bovine alpha-S1 casein gene sequences](#)
- 6797265- [Deleted adenovirus vectors and methods of making and administering the same](#)
- 6783968- [Methods for sterilizing preparations of glycosidases](#)
- 6749851- [Methods for sterilizing preparations of digestive enzymes](#)
- 6716208- [Implantable device and use therefor](#)
- 6610290- [Adeno associated virus vectors for the treatment of a cardiomyopathy](#)
- 6572605- [Implantable device and use therefor](#)
- 6335011- [Methods for delivering DNA to muscle cells using recombinant adeno-associated virus virions to treat lysosomal storage disease](#)
- 6328958- [Deleted adenovirus vectors and methods of making and administering the same](#)

- 6118045- [Lysosomal proteins produced in the milk of transgenic animals](#)
- 5962313- [Adeno-associated virus vectors comprising a gene encoding a lysosomal enzyme](#)
- 5911704- [Implantable device and uses therefor](#)
- 7001994- [Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins](#)
- 7056712- [Treatment of glycogen storage disease type II](#)
- 7598031- [Method for the detection of gene transcripts in blood and uses thereof](#)
- 7560424- [Targeted therapeutic proteins](#)
- 7485314- [Induction of antigen specific immunologic tolerance](#)
- 7396811- [Subcellular targeting of therapeutic proteins](#)
- 7378231- [Diagnosis of lysosomal storage disorders using saposins and other markers](#)
- 7361481- [Diagnosis of lysosomal storage disorders using saposins and other markers](#)
- 7351410- [Treatment of Pompe's disease](#)
- 7341720- [Targeting of glycoprotein therapeutics](#)
- 7329422- [Pharmaceutical compositions](#)
- 7282199- [Adeno-associated virus \(AAV\) serotype 8 sequences, vectors containing same, and uses therefor](#)
- 7129049- [Method of detecting equine glycogen storage disease IV](#)
- 7094604- [Production of pseudotyped recombinant AAV virions](#)
- 5704910- [Implantable device and use therefor](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:Peter.Barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

